Business UpdateJul 14, 2026, 08:35 AM
SeaStar Medical Sponsors Pediatric AKI Initiatives, Webinar
AI Summary
SeaStar Medical Holding Corporation announced its sponsorship of key initiatives to advance the treatment of pediatric acute kidney injury (AKI). The company is sponsoring the KidneyBee Summit 2026 and hosting an educational webinar on August 11, 2026, focusing on its QUELIMMUNE® (SCD-PED) therapy. QUELIMMUNE, approved in February 2024, has shown a 77% survival rate in clinical trials and 76% in real-world data for critically ill pediatric patients with AKI.
Key Highlights
- Sponsoring KidneyBee Summit 2026 at Children’s Hospital Colorado from July 14-16.
- Hosting educational webinar on QUELIMMUNE for pediatric sepsis-associated AKI on August 11, 2026.
- QUELIMMUNE (SCD-PED) therapy was approved in February 2024 under a Humanitarian Device Exemption.
- Clinical trials showed a 77% survival rate for patients treated with QUELIMMUNE.
- Real-world data indicated 76% survival at Day 28 and Day 60, and 71% at Day 90.
- Awarded the 2025 Corporate Innovator Award by the National Kidney Foundation in January 2025.
Price Impact
More from ICU
More in Business Update